(Q38252348)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25233793%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

review article

1 reference

title

CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25233793%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

0 references

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25233793%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Michele Maio

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25233793%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Luana Calabro'

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25233793%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

author name string

Giovanni Luca Ceresoli

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25233793%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Alessandra di Pietro

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25233793%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Ornella Cutaia

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25233793%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Ramy Ibrahim

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25233793%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

publication date

19 September 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25233793%20AND%20SRC:MED&resulttype=core&format=json

Cancer Immunology, Immunotherapy

16 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25233793%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

volume

64

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25233793%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25233793%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

page(s)

105-112

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25233793%20AND%20SRC:MED&resulttype=core&format=json

Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008

16 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9

Multidisciplinary treatment of malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9

Surgery in the treatment of malignant pleural mesothelioma: recruitment into trials should be the default position

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9

Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9

Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9

Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9

Second-line treatment for malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9

Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9

Anti-angiogenic therapies for malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9

BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9

Immunotherapy and the concept of a clinical cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9

Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9

Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9

Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9

Dysregulation of the immune system caused by silica and asbestos

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9

Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9

Asbestos induces reduction of tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9

From the archives of the AFIP. Malignant pleural mesothelioma: radiologic-pathologic correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9

Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9

CT in differential diagnosis of diffuse pleural disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9

Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9

New checkpoint inhibitors ride the immunotherapy tsunami.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9

Epigenetic drugs as immunomodulators for combination therapies in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9

Biomarkers for immune checkpoint inhibitors – Authors' reply

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9

Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1609-9